We detected clonal mosaicism for large chromosomal anomalies (duplications, deletions and uniparental disomy) using SNP microarray data from over 50,000 subjects recruited for genome-wide association studies. This detection method requires a relatively high frequency of cells with the same abnormal karyotype (>5-10%; presumably of clonal origin) in the presence of normal cells. The frequency of detectable clonal mosaicism in peripheral blood is low (<0.5%) from birth until 50 years of age, after which it rapidly rises to 2-3% in the elderly. Many of the mosaic anomalies are characteristic of those found in hematological cancers and identify common deleted regions with genes previously associated with these cancers. Although only 3% of subjects with detectable clonal mosaicism had any record of hematological cancer before DNA sampling, those without a previous diagnosis have an estimated tenfold higher risk of a subsequent hematological cancer (95% confidence interval = 6-18).
A r t i c l e s
Chromosomal mosaicism is the presence of different karyotypes in two or more cell lineages within an individual derived from a single zygote 1, 2 . This karyotypic variation may arise early in development and involve both the soma and the germline or may occur later and be restricted to one or more specific cell types. In cancer, chromosomal anomalies can initiate a neoplastic clone or arise during clonal evolution and serve as clonal markers 3 . Here, we consider such clonal variation as a form of mosaicism, as the cancer cells may have acquired one or more chromosomal abnormalities, whereas other cells in the same tissue or elsewhere in the body retain a normal karyotype. Chromosomal mosaicism in humans has been well studied in embryos 4, 5 , fetuses from spontaneous abortions 6 , children with birth defects or developmental delay 7, 8 and individuals with cancer 9 . However, little is known about the type, frequency and age distribution of acquired chromosomal anomalies in large samples from the general population 9, 10 .
Data from genome-wide association studies provide an opportunity to detect chromosomal variation in tens of thousands of people of all ages and to investigate the association of mosaicism with disease. SNP microarray data are used routinely to detect chromosomal anomalies (copy-number variants (CNVs) and uniparental disomy (UPD)) in clinical cytogenetic laboratories 11, 12 and to detect small CNVs in population studies [13] [14] [15] . However, the analytical methods used in population studies are not optimal for detecting large anomalies or mosaicism. Therefore, we developed an efficient method to identify and map large (50-kb to whole-chromosome) anomalies and mosaicism within a single DNA sample. This method requires a relatively high frequency of cells with the same abnormal karyotype (>5-10%; presumably of clonal origin) in the presence of normal cells. Therefore, we use the term 'detectable clonal mosaicism' rather than 'chromosomal mosaicism' , to emphasize the observation of clones of cells with abnormal karyotype that occurred at a frequency sufficient for detection using SNP microarray data.
To detect clonal mosaicism, we analyzed DNA samples (primarily from peripheral blood) from over 50,000 people genotyped for the Detectable clonal mosaicism from birth to old age and its relationship to cancer the mean number per subject was 1.5 (range 0 to 13). There were 514 mosaic anomalies in 404 of 50,222 subjects analyzed.
The reproducibility (in 568 duplicate sample pairs) of all anomalies analyzed for mosaic status was 82% (with >80% overlap; Online Methods and Supplementary Table 2 ). For clonal mosaic anomalies in duplicate samples, the reproducibility was 68% (15/22) , and all discordant calls seemed to be false negatives, based on examination of BAF and LRR plots. We also assessed the reproducibility of clonal mosaic anomaly calls in comparison to those reported by Jacobs et al. in an accompanying paper 18 , where the same raw data were analyzed for 5,510 subjects from the GENEVA Lung Cancer study. Whereas the methods in both studies detected 83 mosaic anomalies, the GENEVA method described here detected an additional 28 mosaic anomalies (8 of >2 Mb in size), and the Jacobs method detected an additional 20 mosaic anomalies (all of >2 Mb). The overall reproducibility was 63% and was 75% when considering only anomalies greater than 2 Mb in size (the size detection limit of the Jacobs method). Both estimates are considerably greater than the 25-50% reproducibility across methods estimated for several common CNV-calling algorithms 19 . All findings of mosaic events that were discordant seemed to be due to false negatives. The Jacobs method is more conservative with respect to size threshold (2 Mb), whereas our method is more conservative with respect to sample quality (but calls mosaic anomalies involving segments less than 2 Mb in size when sample quality is sufficient). Therefore, the false negative rates of both methods seem high, and the prevalence of clonal mosaic anomalies detected here is likely to be underestimated. Mosaic detection is difficult when the fraction of abnormal cells is extreme, when the anomaly length is small or when sample quality is low (with high BAF and/or LRR variability).
The clonal mosaic anomalies detected in GENEVA subjects were classified as 15.6% duplications, 50.4% deletions and 34.0% aUPD. All three classes of mosaic anomalies were large ( Fig. 4 and Supplementary Fig. 6 ). Median lengths were 34.1 Mb for duplications, 3.8 Mb for deletions and 39.8 Mb for aUPD. Mosaic aneuploidies included +8, +9, +12, +14, +15, +18, +19, -21 and +22, and whole-chromosome mosaic UPD events were found on chromosomes 2, 3, 13, 14 and 15. Plots of the breakpoints of all mosaic anomalies are provided (Supplementary Fig. 7) , and genomic coordinates (along with other information) are given (Supplementary Table 3 ).
There was a highly significant excess of subjects with multiple clonal mosaic events compared to the Poisson distribution expected Fig. 2g) , and (ii) as non-adjacent sets. Among the 404 mosaic subjects, 64 had multiple mosaic anomalies of one or both types (with 2.6 expected), and 55 had only non-adjacent sets (with 2.4 expected). The excess of multiple mosaic anomalies was observed for both CNVs and aUPD. The age of the subjects with multiple anomalies was not significantly different than that of subjects with a single anomaly (P = 0.99).
The frequency of detectable clonal mosaicism increases with age
The observed frequency of subjects with one or more clonal mosaic anomalies detected (the mosaic status) is shown ( Fig. 5 and Supplementary Table 4 ). It was low (<0.5%) in subjects less than 50 years of age but increased with age to 2.7% in subjects over 80. The mosaic frequency was 0.2% in the groups including subjects from 0-14 years old (15/8,535 ) and from 15-29 years old (16/6,739), despite the fact that approximately half of the subjects that were 0-14 years old had a phenotypic abnormality (non-syndromic cleft lip/palate or prematurity or low birth weight). Excluding subjects less than 15 years of age in multiple logistic regression of mosaic status on age at DNA sampling and adjusting for several covariates (study, sex, DNA source and ancestry), we found that age was a highly significant predictor of mosaic status (P = 2 × 10 −16 ; odds ratio (OR) = 1.05, 95% confidence interval (CI) = 1.04-1.07). Among the covariates, only 'study' (defined in Table 1 ) was significant (P = 0.01), and a subsequent test of age-by-study interaction was not significant. It is notable that the DNA source (92% from blood and 8% from saliva/buccal swabs) was not a significant predictor (P = 0.45). When only blood samples were analyzed, the age-effect estimate was the same (to three decimal places), and the P value was only slightly higher (4 × 10 −15 ) than in the combined analysis of both DNA sources. Copy-number mosaic and aUPD anomalies, when tested separately, each had a significant age effect and similar odds ratios (P for gain = 0.01; P for loss = 5 × 10 −11 ; P for aUPD = 6 × 10 −8 ; OR (95% CI) for gain = 1.032 (1.005-1.061); OR (95% CI) for loss = 1.057 (1.039-1.075); OR (95% CI) for aUPD = 1.056 (1.035-1.077)). This age effect was specific for mosaic anomalies. The same logistic regression performed with non-mosaic anomalies did not show a significant age effect (P = 0.11), and the regression coefficient estimate was negative (−0.002), whereas that for mosaic anomalies was positive (0.050) (Supplementary Fig. 8 ). This result indicates that our classification method distinguishes effectively between acquired and constitutional anomalies.
To further explore the robustness of the age effect on clonal mosaicism, we performed additional analyses with each of the seven studies having more than 1,000 subjects over 50 years of age (using both blood and saliva/buccal samples). Only the age effect was significant (P = 8 × 10 −16 ) in a combined logistic regression of mosaic status on study, sex, DNA source, ancestry and smoking status (separately testing either ever or never smokers). When only controls from these studies were analyzed together, the age effect remained highly significant (P = 7 × 10 −11 ). We also analyzed each study separately with age and the case status specific to that study. A meta-analysis showed a highly significant effect of age ( Fig. 6) , which was very robust to differences in both study and subject characteristics.
These cross-sectional analyses strongly suggest that most of the mosaic anomalies detectable by SNP microarrays appear late in life, because they arise more frequently and/or because they are more readily detected due to clonal expansion. This suggestion is supported by longitudinal observation for one GENEVA subject (the only subject sampled twice who had mosaicism in at least one sample). This subject was sampled at age 66 and again at age 72 (both times with DNA from saliva). No mosaic anomalies were detected in the earlier sample, but the later sample contained five mosaic deletions, each on a different chromosome. Additional studies with subjects sampled at multiple ages are needed to evaluate the temporal origin and stability of mosaic anomalies.
In some GENEVA subjects, anomalies seemed to have occurred early enough in development to be mosaic in both the soma and germline. In 35 parent-offspring pairs in which a mosaic anomaly was detected in the parent, there were three cases in which the offspring was non-mosaic for the same anomaly (one deletion and two duplications), and there was no corresponding anomaly (mosaic or otherwise) in the remaining 32 offspring. Although this result suggests that a fairly large proportion of individuals have mosaicism shared by the germline and soma, it may not be representative of the more frequent mosaic anomalies 
npg
A r t i c l e s that occur in older subjects, as parents in the family studies were sampled in their 20s and 30s ( Table 1 ). The mosaic events that occur in subjects less than 50 years of age may have different origins than those that occur later, when the frequency of events increases rapidly.
Mosaic anomalies characteristic of hematological cancers
The clonal mosaic anomalies detected in this study tended to cluster in location within and among chromosome arms ( Fig. 4 and Supplementary Figs. 7 and 9) . Regions with multiple overlapping anomalies frequently coincided with regions of copy-number change or aUPD that are characteristic of hematological cancers. Using the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, we found that 222 of 669 recurrent duplications and deletions found in hematological cancers have >80% overlap with at least one mosaic CNV in GENEVA subjects. Also, 77% of GENEVA mosaic CNVs have >80% overlap with the aberrations in the Mitelman database, and 48% overlap both cytological bands defining the limits of the corresponding aberration. The most common overlaps were of 20q-, 13q-, 11q-, 17p-, 12+ and 8+. Common deleted regions (CDRs) of mosaic anomalies in different GENEVA subjects often mapped to genes previously associated with hematological cancers (Supplementary Fig. 7 , chromosomes 4, 13, 20 and 22). First, at 13q, 31 deletions have a CDR of 299 kb containing only 1 gene, DLEU7, which is thought to be a tumor suppressor 20 . In addition, 18 deletions at 13q include RB1, and 24 include MIR15A and MIR16-1. 
A r t i c l e s
Deletions in this region (13q14) represent the most common cytogenetic abnormality in chronic lymphocytic leukemia (CLL) 21 , which is the most common leukemia in older adults. Second, at 4q, 14 deletions have a CDR of 214 kb containing only 1 gene, TET2, which is commonly deleted in myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD) and acute myeloid leukemia (AML) 22 . Third, at 2p, 17 deletions have a CDR of 194 kb, which contains 2 genes, one of which is DNMT3A, recently found to be commonly mutated in AML-M5 (ref. 23) . Fourth, at 22q, 11 deletions have a CDR of 153 kb, which includes 3 genes, 1 of which is PRAME, which is frequently deleted in CLL 24 . Fifth, at 20q, 46 deletions have a CDR of 965 kb containing 7 genes, including L3MBTL1, which is a candidate tumor suppressor in del(20q12) myeloid disorders 25 . Long (multi-megabase) segments of aUPD are frequently observed in cancers of many types 26 . In most cases, the anomaly causing UPD occurs on a terminal segment of one arm, consistent with this alteration originating from a single mitotic crossover that is followed by outgrowth of one of the daughter cells. aUPD is frequently observed in hematological cancers, such as MDS, MPD and AML, and is associated with homozygosity of mutations in several tumor suppressors and oncogenes 27, 28 . All autosomes (except chromosome 10) had at least one clonal mosaic aUPD anomaly in GENEVA subjects. Chromosomes 9 (with 24 anomalies), 14 (with 21) and 11 (with 19) have the most aUPD anomalies, greatly exceeding the expected number based on arm length (Supplementary Fig. 9 ).
Despite the observation that many of the clonal mosaic anomalies identified here are characteristic of hematological cancer, the proportion of subjects with one or more mosaic anomalies who had a record of hematological cancer before DNA sampling was low. This proportion was estimated to be 2.8% (95% CI = 1.0-4.7%) in 291 mosaic subjects (with DNA from blood from 13 GENEVA studies, using medical records, self-reported conditions and study exclusion criteria as described in the Supplementary Note).
Hematological cancer incidence
We investigated whether detectable clonal mosaicism predisposes to incident hematological cancer after DNA sampling by using three GENEVA studies that included cohorts with cancer diagnosis records both before and after DNA sampling. We analyzed 8,562 subjects who had DNA derived from blood and no record of hematological cancer before DNA sampling from (i) the Glaucoma study, with subjects from the Nurses Health Study (NHS, n = 363) and the Health Professionals Follow-up Study (HPFS, n = 285); (ii) the Lung Cancer study, with subjects from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO, n = 1,600); and (iii) the Prostate Cancer study, with subjects from the Multiethnic Cohort (MEC, n = 6,314). Among the 8,562 subjects analyzed for incident hematological cancer, 8,323 were non-mosaic with no events, 90 were non-mosaic with events, 134 were mosaic with no events, and 15 were mosaic with events (where an event was a hematological cancer diagnosis).
To test for an association between mosaic status and incident hematological cancer, we used a cause-specific Cox proportional hazards model to analyze time to a hematological cancer diagnosis from the date of DNA sampling, with right censoring at death or the endpoint of follow-up data. We performed a stratified analysis of the four cohorts, which included mosaic status and adjusted for age at DNA sampling, non-hematological cancer status (as a time-dependent covariate), ancestry (two principal components) and sex (within the PLCO stratum). The hazard ratio estimate for mosaic status was 10.1 (95% CI = 5.8-17.7) with a P value of 3 × 10 −10 . A meta-analysis showed consistent results among cohorts and gave a very similar effect estimate (Supplementary Fig. 10 ). These results estimate that the risk of hematological cancer is tenfold higher for mosaic than for non-mosaic individuals.
Because the incidences of cancer and the clonal mosaic anomalies detected in this study both increase with age, adjustment for age at time of DNA sampling in the Cox regression model is critical. We modeled the age covariate as either a linear or nonlinear effect (spline Observed mosaic cases Expected leukemia cases Figure 5 The percentage of subjects having one or more mosaic anomaly within 5-year age bins. Vertical bars are 95% confidence intervals. For two cells with zero counts, the upper bar connects zero to the frequency with a lower 95% confidence interval of zero, given the sample size. Expected leukemia values are given for reference and were calculated using ageand sex-specific prevalence estimates from the Surveillance Epidemiology and End Results (SEER) database. Figure 6 Fixed-effects meta-analysis for effect of age at DNA sampling on mosaic status. Effect estimates are from logistic regression of mosaic status on age at DNA sampling, with adjustment for case status specific to each study. The summary estimate of the log OR is 0.05 (95% CI = 0.04-0.07), and the corresponding OR is 1.06 (95% CI = 1.04-1.07). Cochran's Q test of heterogeneity gave P = 0.89. The sizes of the black boxes are proportional to the inverse of the squared standard error, and the gray lines are 95% confidence intervals. The horizontal corners of the diamond span the 95% confidence interval of the summary estimate. For study descriptions, see A r t i c l e s smoothing with 5 degrees of freedom) and found that the mosaic effect estimates and P values were essentially identical. Among the 15 mosaic subjects who had a hematological diagnosis after DNA sampling, 4 had myeloid leukemia, 6 had chronic lymphocytic leukemia, 1 had multiple myeloma, 1 had MDS, 1 had MPD, and 2 had non-Hodgkin lymphoma. Thus, the 15 cases are approximately evenly divided between mature B-cell neoplasms and myeloid malignancies. Not unexpectedly, the leukemias were over-represented in mosaic relative to non-mosaic subjects (P = 0.005; Supplementary Tables 5 and 6). A variety of chromosomal anomalies were found in the mosaic subjects (Supplementary Table 7) . Deletions covering the described CDRs were found in several of these subjects: at 13q-in five CLL cases, at 4q-in one chronic myelogenous leukemia (CML) case, at 20q-in one multiple myeloma case and one AML case and at 22q-in one CLL case. Five of the 15 mosaic subjects with incident hematological cancer had more than one mosaic anomaly, which is a higher proportion than that found in the remaining subjects within these cohorts (25/134), although this increase is not significant (P = 0.18).
Although the risk of incident hematological cancer was estimated as tenfold higher for mosaic than for non-mosaic subjects (95% CI = 5.8-17.7), it is important to note that the incidence rate in mosaic individuals is low (10-year event rate of 0.143, 95% CI = 0.065-0.214; Fig. 7 ) and that only a small fraction of mosaic GENEVA subjects have a record of hematological cancer before DNA sampling (2.8%, 95% CI = 1.0-4.7%). The period between the first appearance of detectable clonal mosaicism and the incidence of hematological cancer is of interest but cannot be estimated from our data, as mosaicism was present for an unknown period of time before DNA sampling. However, the median time of 3.5 years between DNA sampling and hematological cancer diagnosis provides a very rough minimum estimate (range 3.5 months to 10.7 years with n = 15; Fig. 7 ).
Non-hematological cancer
To investigate the relationship between mosaic status and nonhematological cancer, we performed two types of analyses. First, in each of the three GENEVA case-control cancer studies (Lung Cancer, Prostate Cancer and Melanoma), we performed logistic regression of mosaic status on case status and age at DNA sampling. Case status was not a significant factor in any of the three studies or in a metaanalysis (one-tailed P = 0.06). The estimated odds of having a clonal mosaic anomaly was higher among cancer cases than controls in the lung and prostate cancer studies, but lower in the melanoma study (Supplementary Fig. 11 ). Second, in the cohort studies (PLCO, HPFS, NHS and MEC), we performed logistic regression of mosaic status on whether or not the subject had a non-hematological cancer before DNA sampling (excluding any hematological cancer cases). In these analyses, the relationship was consistently positive but small and not significant overall (one-tailed P = 0.11; Supplementary  Fig. 12 ). In summary, the evidence hints at a positive relationship between mosaic status and non-hematological cancer but lacks statistical significance. Therefore, further work is needed in larger sets of non-hematological cancer studies, including data on potential exposure, disease and treatment effects.
DISCUSSION
Here, we have shown that the frequency of subjects with detectable clonal mosaicism for large chromosomal anomalies in peripheral blood is low (<0.5%) from birth until 50 years of age, after which it rises rapidly. This relationship between mosaicism and age is very robust to both study and subject characteristics. Among the covariates of sex, ancestry, smoking status and disease status (exclusive of hematological cancer), none had a significant effect on mosaic status. The age effect in GENEVA subjects is consistent with a recent study showing that acquired differences in structural chromosome variants between members of monozygotic twin pairs (including clonal mosaic anomalies) are observed in pairs of >55 years of age but not in younger pairs 29 . Nevertheless, longitudinal studies are required to rule out the possibility that a trend in environmental exposures across birth cohorts might contribute to the increase in mosaicism with age.
The observed increase in detectable clonal mosaicism late in life may be due to a change in the frequency with which chromosomal anomalies occur (increased somatic mutation rate) and/or their ability to form large clones (clonal expansion). Previous work has shown that the occurrence of chromosomal anomalies (rearrangements and aneuploidies) during cell division increases with age in cultured lymphocytes and fibroblasts 30, 31 , that DNA damage accumulates with age in mouse hematopoietic stem cells 32 and that mitotic recombination (leading to UPD) increases with replicative age in yeast 33 . This apparent increase in somatic mutation may result from age-related decline in genomic maintenance mechanisms (such as telomere attrition 34 ). Clonal expansion of cells containing chromosomal anomalies could be due to either positive selection or to random changes in the frequencies of hematopoietic stem cell descendants. In principle, stem cell senescence and age-related decline in replicative function 35 could result in a decrease in the effective population size of stem cells, leading to shifts in clonal composition analogous to random drift in small populations of individuals 36 . However, analyses of the clonal composition of blood cells in healthy women using X-inactivation markers suggest stability over time and between lymphoid and myeloid lineages, even in the elderly 37, 38 . Therefore, in most cases, positive selection may be required to establish clones of cells with chromosomal anomalies that are sufficiently large for detection with SNP microarrays. The potential for positive selection may increase with age as somatic mutations accumulate in genes that regulate cellular proliferation. For example, a highly proliferative clone may arise when a recessive tumor suppressor mutation becomes hemizygous in npg A r t i c l e s combination with a deletion or homozygous due to aUPD. This suggestion is supported by the observation that acquired anomalies tend to cluster in certain genomic regions and that common deleted regions map to genes previously associated with hematological cancer.
In the mosaic individuals described in this study, the chromosomally abnormal cells constitute a substantial fraction of white blood cells, as a minimum of 5-10% is required for detection by our method, and many abnormal clones are substantially larger (Fig. 2) . The blood samples used for DNA extraction were not fractionated by white blood cell type. The abnormal blood cells within an individual might include multiple cell types if the anomaly arose in a multipotent hematopoietic stem cell that became predominant due to senescence or positive selection within the stem cell population. Alternatively, the abnormal cells might include a restricted set of cell types, particularly when the normal composition of blood (which is 60-70% neutrophils and 20-40% lymphocytes 39 ) is altered by unregulated proliferation 40 .
There is a strong association between the clonal mosaic anomalies detected in our study and hematological cancer. We estimate the risk of acquiring a hematological cancer diagnosis as tenfold higher for subjects with mosaic anomalies. This association is strongly supported by the finding that many of the mosaic anomalies are characteristic of those found in hematological cancers. Nevertheless, the event numbers analyzed here are small, and additional studies are needed across a broader diversity of cohorts to establish the clinical importance of these findings.
Notwithstanding the strong association with hematological cancer, we estimated that ~97% of subjects with clonal mosaic anomalies did not have a record of a hematological cancer before DNA sampling, and the incidence rate of such cancer was low (~14% over 10 years in subjects who survived and were not lost to follow-up analysis during this period). These results suggest that the clonal mosaicism observed in elderly subjects may be an asymptomatic condition with a predisposition to hematological cancer that is often not realized.
It is possible that many of the subjects with detectable clonal mosaicism in our study have monoclonal B-cell lymphocytosis (MBL), an asymptomatic condition with an estimated prevalence of 3-5% in the elderly. MBL is characterized by a clonal population of B lymphocytes with an immunophenotype similar to CLL or other B-cell malignancy 41 . Most, if not all, cases of CLL are preceded by MBL, but most cases of MBL do not progress to malignancy 42, 43 . However, 85% of MBL cases detected in population screening studies have a B-cell count below 500 cells/µl (ref. 43) , which is less than 10% of the normal white blood cell count. Because 10% is near the lower limit of detection for chromosomal mosaicism using our methods, the two types of clones may not be closely related. Nevertheless, further work on the relationship between B-cell immunophenotypes and mosaic anomalies is warranted.
Although it seems that most of the clonal mosaicism observed in GENEVA subjects represents a non-malignant condition, further work is needed to evaluate the fraction of subjects who might have unrecorded malignant conditions, such as MDS and MPD, or undiagnosed CLL. MDS and MPD were added to the Surveillance, Epidemiology, and End Results (SEER) cancer registries in 2001 and may still be under-recorded, because they are often managed outside of the hospital setting 44 . Therefore, accurate prevalence data from widespread populations are not available, but local population estimates (0.1% MDS 45 and 0.5% MPD 46 in the elderly) are substantially less than the ~2.5% of GENEVA subjects with mosaic anomalies who were over 75 years old.
This survey is the first large-scale study of acquired chromosomal anomalies in people of all ages and various states of health. Previously, the extent of chromosomal variation within developmentally normal individuals in the absence of overt cancer was largely unknown. The results presented here indicate that a substantial fraction of blood cells in people without a history of hematological cancer may contain large chromosomal anomalies, including multi-megabase deletions, duplications and aUPD anomalies. The frequency of people with such clonal anomalies in a mosaic state is low up to approximately 50 years of age and then increases rapidly up to 2-3% with advanced age. We find that these anomalies are associated with an approximately tenfold higher risk of hematological cancer, but subjects with detectable clonal mosaicism may survive for years without having a hematological cancer diagnosis. Further work is needed to determine the stability of the mosaic state over time, to replicate and improve estimates of predisposition to hematological cancer and to identify anomalies associated with asymptomatic cancer precursor conditions. It also will be important to explore the health consequences of these anomalies for conditions other than cancer, such as altered immune system function. 
METHODS
Methods and any associated references are available in the online version of the paper.
Accession numbers.
Data from these studies are available at dbGaP (phs000187.v1.p1, phs000335.v2.p2, phs000094.v1.p1, phs000092. v1.p1, phs000093.v2.p2, phs000304.v1.p1, phs000306.v3.p1, phs000289.v2.p1, phs000096.v4.p1, phs000095.v1.p1, phs000103. v1.p1 and phs000308.v1.p1) (see also Supplementary Table 1) .
Note: Supplementary information is available in the online version of the paper.
A r t i c l e s (BAF deviation > 0.25) that had much smaller LRR deviations than expected for disomic-trisomic or disomic-monosomic transitions and included very few interstitial anomalies (Supplementary Fig. 3 ). All other anomalies (except for a few outliers) were classified as either duplications or deletions, depending on the sign of their LRR deviation. There was some ambiguity in classifying anomalies near the tip of the arrow, where the three transition zones intersect. This ambiguity is noted as intensity.flag (Supplementary Table 3 ). Mixture proportions in mosaics can be estimated as position along the transitional line that connects the two constitutional states (Fig. 2 and Supplementary Note).
All anomalies discussed here are autosomal in the reference genome. Detection of X-chromosome mosaic anomalies is complicated by the fact that LRR is a measure of the intensity of a sample relative to other samples. LRR values for the X chromosome (calculated in the standard way) are affected by the sex ratio in the sample set and are not comparable to those for the autosomes.
Statistical analysis. All statistical analyses were carried out in the R statistical package using the functions described in the Supplementary Note.
